MOREPEN LABORATORIES LTD.

Morepen Laboratories Ltd announced the resignation of Mr. Bhola Prasad, General Manager – Process Engineering & Technology Transfer, a functional head and Senior Management Personnel. His resignation is effective July 6, 2026, due to personal reasons and a desire for career growth outside the company. The company has enclosed the resignation letter and provided details as required by SEBI Listing Regulations. Mr. Prasad has assured a smooth handover of his responsibilities.

Morepen Laboratories Limited has commenced commercial supplies under its significant ₹825 crore CDMO (Contract Development and Manufacturing Organization) mandate. The company announced the completion of its first dispatch, valued at approximately ₹50 crore, in Q1FY2026-27. This marks a crucial transition from the validation phase to commercial execution. Morepen anticipates further scaling up operations, with an estimated ₹225 crore in additional supplies expected in Q2FY2026-27. To support this growth, the company is expanding its manufacturing infrastructure, aiming for 600 KL reactor capacity by the end of Q2 and further expansion to 800 KL and 1,000 KL in subsequent phases. This move reinforces Morepen's strategy to build a robust CDMO platform and secure long-term global manufacturing partnerships.

Morepen Laboratories Ltd. announced the elevation of Mr. Sanjay Suri from Whole-time Director to Managing Director, effective July 1, 2026. This decision was made by the Board of Directors on June 30, 2026, based on the Nomination and Remuneration Committee's recommendation. His new role is for the balance of his existing term, until August 12, 2028, subject to shareholder approval. As Managing Director, Mr. Sanjay Suri will jointly oversee the company's management and operations alongside Mr. Sushil Suri, the Chairman & Managing Director. Mr. Sanjay Suri, a Bachelor of Science, brings over thirty years of experience in the pharmaceuticals industry, covering international sales, marketing, joint ventures, regulatory approvals (including USFDA), strategic planning, manufacturing, finance, accounts, and banking. He is also a member of the promoter group and brother of Mr. Sushil Suri.

Morepen Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from July 1, 2026, and will continue until 48 hours after the announcement of the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent any potential insider trading activities during the period leading up to and immediately following the financial results disclosure.

Morepen Laboratories Ltd has responded to stock exchange queries regarding a recent surge in its share volume. The company clarified that it regularly intimates all compliances as per SEBI (LODR) Regulations, 2015. Morepen Laboratories confirmed that there are no pending announcements, events, or price-sensitive information that could explain the significant increase in trading volume. The company suggested that the market activity may be driven by general market trends.

Morepen Laboratories Ltd reported a 69% YoY increase in net profit to ₹20 crore for Q4 FY26, with gross revenue up 22% YoY to ₹472 crore. The growth was driven by export momentum and expansion in the Medical Devices business. The board has proposed a 10% dividend for FY26. Commercial production has commenced under a long-duration CDMO program. Capacity expansion is underway from ~500 KL toward ~800 KL. FY26 standalone gross revenue crossed ₹1,700 Cr, up 8%.

Morepen Laboratories Ltd's board approved the second addendum to the Business Transfer Agreement with its subsidiary, Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026, and recommended a final dividend of ₹0.20 per equity share. Additionally, M/s. Vijender Sharma & Co. were re-appointed as Cost Auditors for FY27.

Morepen Laboratories Ltd's board approved the second addendum to the Business Transfer Agreement with its subsidiary, Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026, and recommended a final dividend of ₹0.20 per equity share. Additionally, M/s. Vijender Sharma & Co. was re-appointed as Cost Auditors for FY27.

Morepen Laboratories Ltd's board re-appointed M/s. Vijender Sharma & Co. as Cost Auditors for the financial year ending March 31, 2027, following the Audit Committee's recommendation. This decision complies with the Companies Act, 2013 and related rules. The board also approved the second addendum to the Business Transfer Agreement with its subsidiary, Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. Additionally, the board recommended a final dividend of ₹0.20 per equity share for FY26, subject to shareholder approval.

Morepen Laboratories Ltd's board approved the second addendum to the Business Transfer Agreement with Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. The board also approved the audited standalone & consolidated financial results for the year ended March 31, 2026, and recommended a final dividend of ₹0.20 per equity share. Additionally, M/s. Vijender Sharma & Co. was re-appointed as Cost Auditors for FY27.